Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Zogenix, Inc. (ZGNX) PT Raised to $65 at Mizuho Securities
June 28, 2019 7:36 AM EDTMizuho Securities analyst Difei Yang raised the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $65.00 (from $58.00) while maintaining a Buy rating following the FDA's decision to allow a re-submission of the NDA for FINTEPLA.
Based on final meeting minutes, the FDA... More
